Consensus Revance Therapeutics, Inc.

Equities

RVNC

US7613301099

Real-time Estimate Cboe BZX Other stock markets 01:02:01 2024-05-17 pm EDT			5-day change	1st Jan Change
3.105 ^USD	-1.74%		-5.27%	-64.22%

May. 10	Needham Adjusts Price Target on Revance Therapeutics to $12 From $18, Maintains Buy Rating	MT
May. 10	Piper Sandler Cuts Price Target on Revance Therapeutics to $11 From $20, Maintains Overweight Rating	MT

Evolution of the average Target Price on Revance Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

c8b01b2dbf3e12e903bd8cc379ab.e7MhNHEsjTOFIV_3287lp2LI7VZP8sQjCzYYX9J3W5c.PIdQfiBJoFbVZBOorPawzRWuoToJnLJ3Q3NwB7oRE9YN9m8EIEK_A6hEMA~46df82286e34c8a05f9d6f4eeb771ff1

Analyst Recommendations on Revance Therapeutics, Inc.

Needham Adjusts Price Target on Revance Therapeutics to $12 From $18, Maintains Buy Rating	May. 10	MT
Piper Sandler Cuts Price Target on Revance Therapeutics to $11 From $20, Maintains Overweight Rating	May. 10	MT
Goldman Sachs Adjusts Price Target on Revance Therapeutics to $9 From $8, Maintains Neutral Rating	Mar. 01	MT
Needham Cuts Price Target on Revance Therapeutics to $18 From $20, Maintains Buy Rating	Feb. 29	MT
Piper Sandler Cuts Price Target on Revance Therapeutics to $20 From $42, Maintains Overweight Rating	Feb. 29	MT
Mizuho Securities Downgrades Revance Therapeutics to Neutral From Buy, Lowers Price Target to $9 From $16	Jan. 29	MT
Needham Cuts Price Target on Revance Therapeutics to $20 From $25, Maintains Buy Rating	Jan. 09	MT
Goldman Sachs Downgrades Revance Therapeutics to Neutral From Buy, Cuts Price Target to $8 From $30	Jan. 09	MT
Mizuho Adjusts Revance Therapeutics' Price Target to $16 From $35, Maintains Buy Rating	Nov. 22	MT
Piper Sandler Adjusts Revance Therapeutics' Price Target to $42 From $44, Maintains Overweight Rating	Nov. 09	MT
Needham Adjusts Revance Therapeutics Price Target to $25 From $35, Maintains Buy Rating	Nov. 09	MT
HC Wainwright Adjusts Revance Therapeutics' Price Target to $15 From $41, Keeps Buy Rating	Nov. 06	MT
Barclays Adjusts Revance Therapeutics' Price Target to $35 From $40, Maintains Overweight Rating	23-10-23	MT
Morgan Stanley Lowers Price Target on Revance Therapeutics to $12 From $25, Maintains Equalweight Rating	23-10-11	MT
Goldman Sachs Adjusts Revance Therapeutics' Price Target to $33 From $38, Keeps Buy Rating	23-09-21	MT
Piper Sandler Adjusts Price Target on Revance Therapeutics to $44 From $50, Maintains Overweight Rating	23-09-20	MT
Needham Adjusts Revance Therapeutics Price Target to $35 From $40, Maintains Buy Rating	23-09-20	MT
BNP Paribas Exane Upgrades Revance Therapeutics to Neutral From Underperform, Price Target is $20	23-08-16	MT
Morgan Stanley Adjusts Price Target on Revance Therapeutics to $25 From $26, Maintains Equal-Weight Rating	23-08-09	MT
Needham Adjusts Price Target on Revance Therapeutics to $40 From $44, Maintains Buy Rating	23-08-09	MT
HC Wainwright Adjusts Price Target on Revance Therapeutics to $41 From $48, Maintains Buy Rating	23-08-09	MT
Mizuho Securities Adjusts Revance Therapeutics Price Target to $35 From $33, Maintains Buy Rating	23-06-07	MT
HC Wainwright Adjusts Price Target on Revance Therapeutics to $48 From $42, Maintains Buy Rating	23-05-10	MT
Barclays Adjusts Price Target on Revance Therapeutics to $40 From $37, Maintains Overweight Rating	23-03-01	MT
Needham Adjusts Price Target on Revance Therapeutics to $40 From $38, Keeps Buy Rating	23-03-01	MT